(Q46911787)

English

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

scientific article published in March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

Mario Ojeda-uribe

14

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

author name string

L Legros

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

E Raffoux

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

X Thomas

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

P Turlure

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

S Maury

6

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

B Dupriez

7

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

A Pigneux

8

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

B Choufi

9

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

O Reman

10

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

D Stéphane

11

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

B Royer

12

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

M Vigier

13

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

C Recher

15

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

H Dombret

16

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

F Huguet

17

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

P Rousselot

18

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

Intergroupe Français des Leucémies Myéloïdes Chronique

19

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

Group for Research in Adult Acute Lymphoblastic Leukemia

20

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

20

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

400-403

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404115

0 references

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

21 January 2018

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404115

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404115

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16437142

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46911787&oldid=2137618087"